Ms. Dimond is a Senior Program Officer / Program Director with extensive National Institutes of Health (NIH) and National Cancer Institute (NCI) experience in cancer prevention, symptom science, cardiotoxicity, clinical trials, and cross-institute research coordination. She began her career as an oncology nurse in the NIH Clinical Center and has over thirty years of clinical research experience in both the intramural and extramural programs at NCI. She provides expertise in research program planning, policy development, scientific evaluation, grant portfolio management, and national-level scientific communication to the NCI. She specifically provides clinical and programmatic leadership to the Cancer Prevention Clinical Trials Network to facilitate clinical trials operations in early phase prevention trials exercising decision making on feasibility, scientific priority, and resource allocation across early phase clinical trials from concept to protocol. She leads NIH-wide cardio-oncology collaborations; cross institute scientific planning and has co-imitated funding opportunity development and performed concept reviews supporting NIH cardio oncology research strategy. As an NIH Program Officer, she oversees a portfolio for a cancer treatment-related cardiotoxicity grants and enjoys working with grantees and Principal Investigators on grant aim feasibility and NIH and NCI programmatic alignment. She has organized National NCI scientific webinars, symposia and workshops and is an Author/Co-author of many peer-reviewed publications. She has received NIH and NCI Director’s awards for her work in cancer treatment-related cardiotoxicity efforts and for NCI Community Oncology Research Program (NCORP) Launch Team work. She is most proud of her Distinguished Nurse Award from the NIH Clinical Center and her University of Scranton, Nursing Alumni, Superior Achievement in Nursing Award.

Research Interests

• Cancer treatment related cardiotoxicity and cardio-oncology
• Programmatic infrastructure for effective clinical trial implementation
• Cancer control (symptom management, quality of life, and prevention) trial development